Neurosense Therapeutics Stock Price on October 1, 2024
| NRSN Stock | USD 0.90 0.02 2.17% |
If you're considering investing in Neurosense Stock, it is important to understand the factors that can impact its price. As of today, the current price of Neurosense Therapeutics stands at 0.90, as last reported on the 24th of November, with the highest price reaching 0.96 and the lowest price hitting 0.85 during the day. Neurosense Therapeutics appears to be very risky, given 3 months investment horizon. Neurosense Therapeutics has Sharpe Ratio of 0.0559, which conveys that the firm had a 0.0559% return per unit of risk over the last 3 months. We have found thirty technical indicators for Neurosense Therapeutics, which you can use to evaluate the volatility of the firm. Please exercise Neurosense Therapeutics' Downside Deviation of 4.87, mean deviation of 3.78, and Risk Adjusted Performance of 0.0459 to check out if our risk estimates are consistent with your expectations.
At this time, Neurosense Therapeutics' Common Stock Shares Outstanding is very stable compared to the past year. As of the 24th of November 2024, Liabilities And Stockholders Equity is likely to grow to about 5.3 M, though Total Stockholder Equity is likely to grow to (1.8 M). . As of the 24th of November 2024, Price Earnings Ratio is likely to drop to -1.11. In addition to that, Price Book Value Ratio is likely to grow to -5.43. Neurosense Stock price history is provided at the adjusted basis, taking into account all of the recent filings.
Neurosense |
Sharpe Ratio = 0.0559
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | NRSN | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 5.43 actual daily | 48 52% of assets are more volatile |
Expected Return
| 0.3 actual daily | 5 95% of assets have higher returns |
Risk-Adjusted Return
| 0.06 actual daily | 4 96% of assets perform better |
Based on monthly moving average Neurosense Therapeutics is performing at about 4% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Neurosense Therapeutics by adding it to a well-diversified portfolio.
Price Book 4.1496 | Book Value (0.09) | Enterprise Value 16.7 M | Enterprise Value Ebitda (1.16) | Shares Float 13.5 M |
Related Headline
Neurobo Pharmaceuticals Headline on 1st of October 2024
NRBO Positive SAD Part 1 Data MAD Part 2 Results Expected in... by finance.yahoo.com
By David Bautz, PhD NASDAQNRBO READ THE FULL NRBO RESEARCH REPORT On September 30, 2024, NeuroBo Pharmaceuticals, Inc. announced positive topline results for the single ascending dose Part 1 of the ongoing Phase 1 clinical trial of DA-1726 for the treatment of obesity. A total of 45 obese but otherwise healthy individuals were randomized in a double blind, 63 ratio to
Neurosense Therapeutics Valuation on October 1, 2024
It is possible to determine the worth of Neurosense Therapeutics on a given historical date. On October 1, 2024 Neurosense was worth 1.23 at the beginning of the trading date compared to the closed value of 1.22. We use multiple weighted factors in our valuation methodologies to arrive at the intrinsic value of Neurosense Therapeutics stock. Still, in general, we apply an absolute valuation method to find Neurosense Therapeutics' value based on its fundamental and technical indicators available within our service. As compared to an absolute model, our relative valuation model uses a comparative analysis of Neurosense Therapeutics where we calculate exposure to its market risk and evaluate relevant financial multiples and ratios against Neurosense Therapeutics' related companies.
| Open | High | Low | Close | Volume | |
| 1.27 | 1.37 | 1.24 | 1.27 | 64,972 | |
10/01/2024 | 1.23 | 1.23 | 1.17 | 1.22 | 65,843 |
| 1.20 | 1.24 | 1.20 | 1.21 | 27,884 |
| Backtest Neurosense Therapeutics | | | Neurosense Therapeutics History | | | Neurosense Therapeutics Valuation | Previous | Next |
Neurosense Therapeutics Trading Date Momentum on October 1, 2024
| On October 02 2024 Neurosense Therapeutics was traded for 1.21 at the closing time. The top price for the day was 1.24 and the lowest listed price was 1.20 . The trading volume for the day was 27.9 K. The trading history from October 2, 2024 was a factor to the next trading day price decrease. The trading delta at closing time against the next closing price was 0.82% . The trading delta at closing time against the current closing price is 0.00% . |
Neurosense Therapeutics Fundamentals Correlations and Trends
By evaluating Neurosense Therapeutics' financials over time, investors can gain insight into future company performance. However, you can also analyze the published financial statements to find patterns among Neurosense Therapeutics' main balance sheet or income statement drivers and many other relevant indicators that can statistically be found significantly correlated or uncorrelated. Neurosense financial account trend analysis is a perfect complement when working with valuation or volatility modules.About Neurosense Therapeutics Stock history
Neurosense Therapeutics investors dedicate a lot of time and effort to gaining insight into how a market's past behavior relates to its future. Access to timely market data for Neurosense is vital when making an investment decision, and regardless of whether you use fundamental or technical analysis, your return on investment in Neurosense Therapeutics will depend on recognizing future opportunities and eliminating past mistakes. Historical data analysis is the study of market behavior over a given time. Recorded market-related data such as price, volatility, and volume can be quantified and studied over a defined period. Through a detailed examination of a market's past behavior, traders and investors can gain perspective on the inner workings of that market. The information obtained throughout analyzing Neurosense Therapeutics stock prices may prove useful in developing a viable investing in Neurosense Therapeutics
| Last Reported | Projected for Next Year | ||
| Common Stock Shares Outstanding | 13.6 M | 14.3 M | |
| Net Loss | -3.6 M | -3.8 M |
Neurosense Therapeutics Stock Technical Analysis
Neurosense Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
Price Boundaries
Neurosense Therapeutics Period Price Range
Low | November 24, 2024
| High |
0.00 | 0.00 |
Neurosense Therapeutics cannot be verified against its exchange. Please verify the symbol is currently traded on NASDAQ Exchange. If you still believe the symbol you are trying to look up is valid, please let us know, and we will check it as soon as possible.
Neurosense Therapeutics November 24, 2024 Market Strength
Market strength indicators help investors to evaluate how Neurosense Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Neurosense Therapeutics shares will generate the highest return on investment. By undertsting and applying Neurosense Therapeutics stock market strength indicators, traders can identify Neurosense Therapeutics entry and exit signals to maximize returns
Neurosense Therapeutics Technical and Predictive Indicators
Predictive indicators are helping investors to find signals for Neurosense Therapeutics' price direction in advance. Along with the technical and fundamental analysis of Neurosense Stock historical price patterns, it is also worthwhile for investors to track various predictive indicators of Neurosense to make sure they correctly time the market and exploit it's hidden potentials. Even though most predictive indicators are useful for the short-term horizon, it's virtually impossible to predict the unforeseen market. For traders with a short-term horizon, predictive indicators add value when properly applied. Long-term investors, however, may find many predictive indicators less useful.
| Risk Adjusted Performance | 0.0459 | |||
| Jensen Alpha | 0.088 | |||
| Total Risk Alpha | (0.60) | |||
| Sortino Ratio | 0.0271 | |||
| Treynor Ratio | 0.1854 |
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neurosense Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. To learn how to invest in Neurosense Stock, please use our How to Invest in Neurosense Therapeutics guide.You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neurosense Therapeutics. If investors know Neurosense will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neurosense Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.65) | Return On Assets (1.51) | Return On Equity (4.95) |
The market value of Neurosense Therapeutics is measured differently than its book value, which is the value of Neurosense that is recorded on the company's balance sheet. Investors also form their own opinion of Neurosense Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Neurosense Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neurosense Therapeutics' market value can be influenced by many factors that don't directly affect Neurosense Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Neurosense Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Neurosense Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neurosense Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.